Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences
Journal Flyer
Flyer image
Defining the impact of immunomodulators and thrombin generation profile in patients with active multiple myeloma: The roadmap study
International Conference on Hematology and Oncology
June 29-July 01, 2017 Bangkok, Thailand

Patrick Van Dreden, Loula Papageorgiou, Despina Fotiou, Gueye Mor Seny, Laurent Garderet, Evagelos Terpos, Stella Salta, Theodoros Sergentanis, Athanasios Dimopoulos, Annette K Larsen, Ismail Elalamy and Grigoris T Gerotziafas,

Diagnostica Stago, Asni�?¨res-sur-Seine, France
University of Athens, Greece
H�?´pital Saint-Antoine, France
H�?´pital Tenon (AP-HP), France
Centre de Recherche Saint Antoine - INSERM, France

Posters & Accepted Abstracts: J Blood Disord Transfus


Background: Multiple myeloma (MM) and the associated immunomodulatory (IMiD) treatments are associated with risk of vascular complications. Thrombin generation (TG) assessment reflects the equilibrium between procoagulant and anticoagulant activities in the plasma. Aim: We conducted a multicenter study to explore the relationship between stages of MM and alterations of thrombin generation profile. Methods: Patients with MM (n=129) were recruited from July 2014 to December 2016 and stratified to the following groups: 44 newly diagnosed treatment-na�?¯ve patients (ND), 33 patients receiving IMiDs (IM), 45 in complete remission (CR) and 7 patients in partial remission on IMiDs (PR/IM). Patients on anticoagulant treatment were excluded from the study. The control group (CG) consisted of 30 healthy age and sex-matched individuals. Samples of platelet-poor plasma (PPP) were assessed for thrombin generation (TG) with the TF 5pM PPP-Reagent�?® on Calibrated Automated Thrombogram (Stago, France). The upper and lower normal limits (LNL and UNL) were calculated by the mean�?±2 SD. Results: Patients with ongoing MM (ND, IM, PR/IM) had significantly lower peak, ETP and MRI as compared to the CG. In contrast, patients in CR had peak, ETP, MRI values similar to the CG. Patients with PR had lower ETP and MRI values as compared to the CR group (Table 1). In ND 8% had TG>UNL and 20% had TGUNL and 57% had TGUNL and 33% had TGUNL and 14% had TG

Biography :

Patrick Van Dreden is a Head of Clinical Research Department and Prospective Research Manager at Diagnostics Stago. He has Degree of Hemostasis study: Pathogenesis and pharmacology of thrombosis. He is an International Member of Society of Haemostasis and Thrombosis, Member of the European Thrombosis Research Organization, Member of the Mediterranean League against Thromboembolic Diseases, Member of the American Society of Hematology and Member of International Academy of Clinical and Applied Thrombosis/Hemostasis.